Posts By: Kalyn Dabbs

Diabetes is the most expensive chronic illness in the U.S., with $1 of every $4 in healthcare costs going to care for diabetics. The National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) estimates that $237 billion is spent directly on diabetes-related medical costs every year, while another $90 billion is lost each year due to reduced productivity associated with diabetes.

Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer

ODD is in addition to Three FDA Fast Track Designations

Genprex announced the closing of its previously announced registered direct offering to healthcare-focused institutional investors of 7,425,744 shares of the Company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant.  The offering was priced at-the-market under the Nasdaq rules. 

Genprex has entered into definitive agreements with healthcare-focused institutional investors for the sale and issuance of 7,425,744 shares of the Company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules

Latest license creates a comprehensive panel of gene therapies exclusively licensed by Genprex for the Company’s diabetes gene therapy program

Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. In this interview, Varner and Confer discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline.

Provides Additional Protection in Large Markets for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Third FDA Fast Track Designation Further Validates the Potential of REQORSA

AUSTIN, Texas — (June 28, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S.